Inobrodib, pomalidomide and dexamethasone in relapsed or refractory multiple myeloma

• Research type

  Research Study

• Full title

  A Phase II, Open-Label, Multicenter Study of Inobrodib in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

• IRAS ID

  1012518

• Contact name

  Neil McDonald

• Contact email

  regulatory@cellcentric.com

• Sponsor organisation

  CellCentric Ltd

• Clinicaltrials.gov Identifier

  NCT07096778

• Research summary

  The purpose of this study is to learn more about the anti-cancer activity of inobrodib, when given in combination with pomalidomide and dexamethasone, in patients with multiple myeloma that has come back following treatment and which no longer responds to any available therapies. The study treatment will not be compared to any other treatment and patients will know what treatment they are receiving. This study will also further explore the side effects of inobrodib in combination with these other medicines.

• REC name

  Yorkshire & The Humber - Sheffield Research Ethics Committee

• REC reference

  25/YH/0174

• Date of REC Opinion

  16 Sep 2025

• REC opinion

  Further Information Favourable Opinion